Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC raised its position in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 39.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 491,601 shares of the company's stock after purchasing an additional 137,905 shares during the quarter. Geode Capital Management LLC owned about 0.85% of Rezolute worth $2,385,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in RZLT. MML Investors Services LLC purchased a new stake in Rezolute in the 3rd quarter valued at about $57,000. XTX Topco Ltd raised its stake in shares of Rezolute by 67.4% in the 3rd quarter. XTX Topco Ltd now owns 56,375 shares of the company's stock valued at $273,000 after acquiring an additional 22,704 shares during the period. State Street Corp lifted its holdings in shares of Rezolute by 11.6% in the 3rd quarter. State Street Corp now owns 125,472 shares of the company's stock worth $609,000 after acquiring an additional 13,000 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Rezolute during the 3rd quarter worth approximately $239,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Rezolute in the 3rd quarter valued at approximately $65,000. Hedge funds and other institutional investors own 82.97% of the company's stock.

Rezolute Stock Performance

Shares of RZLT traded down $0.22 during midday trading on Wednesday, hitting $5.21. The company had a trading volume of 258,738 shares, compared to its average volume of 435,808. Rezolute, Inc. has a 1 year low of $0.90 and a 1 year high of $6.19. The firm has a market capitalization of $301.88 million, a P/E ratio of -4.10 and a beta of 1.08. The company's 50-day simple moving average is $5.05 and its 200-day simple moving average is $4.80.

Insider Buying and Selling

In other Rezolute news, CFO Daron Evans acquired 9,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $4.60 per share, with a total value of $41,400.00. Following the transaction, the chief financial officer now owns 140,900 shares in the company, valued at $648,140. The trade was a 6.82 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 18.39% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

RZLT has been the topic of a number of research reports. JMP Securities restated a "market outperform" rating and set a $7.00 price target on shares of Rezolute in a research note on Friday, September 20th. Wedbush reissued an "outperform" rating and set a $112.00 target price on shares of Rezolute in a research note on Monday, November 4th. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 target price on shares of Rezolute in a research report on Friday, November 8th. Finally, BTIG Research increased their price target on shares of Rezolute from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, September 10th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Rezolute currently has an average rating of "Buy" and an average price target of $24.13.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.